Journal
CANCERS
Volume 14, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/cancers14030694
Keywords
bladder cancer; checkpoint inhibition therapy; Bacillus Calmette-Guerin; BCG; non muscle invasive; NMIBC; nadofaragene firadenovec; oncolytic viruses
Categories
Ask authors/readers for more resources
In non-muscle-invasive bladder cancer, immune-modulating therapies and oncolytic virus instillations show good efficacy without significant systemic adverse events. Recombinant BCG and recombinant pox-viral vector vaccines need further investigation, and interleukin mediating therapies are currently being studied.
Simple Summary In Bacillus Calmette-Guerin (BCG) refractory non-muscle-invasive bladder cancer (NMIBC), radical cystectomy is the gold standard. The advent of immune checkpoint inhibitors (CPI) has permanently changed the therapy landscape of bladder cancer (BC). Immune-modulating (IM) therapies can offer a chance for bladder preservation in the treatment of NMIBC. This systematic review includes four full-text articles and four congress abstracts with IM agents in this setting. Durvalumab plus Oportuzumab monatox, Pembrolizumab, and Nadofaragene firadenovec (NF) show complete response (CR) rates of 41.6%, 40.6%, and 59.6% after 3 months. Instillations with oncolytic viruses such as NF and CG0070 show good efficacy without triggering significant immune-mediated systemic adverse events. Recombinant BCG VPM1002BC could prove to be valid as an alternative to BCG in the future. The recombinant pox-viral vector vaccine PANVAC (TM) is not convincing in combination with BCG. Interleukin mediating therapies, such as ALT-803, are currently being studied. Background: In Bacillus Calmette-Guerin (BCG) refractory non-muscle-invasive bladder cancer (NMIBC), radical cystectomy is the gold standard. The advent of immune checkpoint inhibitors (CPIs) has permanently changed the therapy landscape of bladder cancer (BC). This article presents a systematic review of immune-modulating (IM) therapies (CPIs and others) in BCG-refractory NMIBC. Methods: In total, 406 articles were identified through data bank research in PubMed/Medline, with data cutoff in October 2021. Four full-text articles and four additional congress abstracts were included in the review. Results: Durvalumab plus Oportuzumab monatox, Pembrolizumab, and Nadofaragene firadenovec (NF) show complete response (CR) rates of 41.6%, 40.6%, and 59.6% after 3 months, with a long-lasting effect, especially for NF (12-month CR rate of 30.5%). Instillations with oncolytic viruses such as NF and CG0070 show good efficacy without triggering significant immune-mediated systemic adverse events. Recombinant BCG VPM1002BC could prove to be valid as an alternative to BCG in the future. The recombinant pox-viral vector vaccine PANVAC (TM) is not convincing in combination with BCG. Interleukin mediating therapies, such as ALT-803, are currently being studied. Conclusion: CPIs and other IM agents now offer an increasing opportunity for bladder-preserving strategies. Studies on different substances are ongoing and will yield new findings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available